BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:33 PM
 | 
Sep 07, 2012
 |  BC Extra  |  Company News

J&J submits Xarelto responses

Johnson & Johnson (NYSE:JNJ) submitted a response to an FDA complete response letter for an sNDA for Xarelto rivaroxaban to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). FDA issued the letter in June after the Cardiovascular and Renal Drugs Advisory Committee voted 6-4...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >